Use of single MRI and 18F-FDG PET-CT scans in both diagnosis and radiotherapy treatment planning in patients with head and neck cancer: Advantage on target volume and critical organ delineation

Head and Neck

Volumn 31, Issue 4, 2009, Pages 461-467

  Gardner, Miriam ^a   Halimi, Philippe ^b   Valinta, Danielle ^a   Plantet, Marie Madeleine ^a   Alberini, Jean Louis ^a   Wartski, Myriam ^a   Banal, Alain ^a   Hans, Stephane ^b   Floiras, Jean Louis ^a   Housset, Martin ^b   Labib, Alain ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

18F FDG PET CT; Head and neck cancer; Interobserver variability; MRI; Radiotherapy treatment planning

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; IMAGING SYSTEM; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; MALE; MASK; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX CARCINOMA; PAROTID GLAND; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOLOGIST; SALIVARY GLAND; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING;

ADULT; AGED; CARCINOMA; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PAROTID GLAND; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 65649122692     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21005     Document Type: Article

References (39)

1. Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 2003;57:49-60. (Pubitemid 36959738)
2. Eisbruch A, Foote RL, O'Sullivan B, Beitler JJ, Vikram B. Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. Semin Radiat Oncol 2002;12:238-249. (Pubitemid 34755930)
3. Khoo VS, Dearnaley DP, Finnigan DJ, Padhani A, Tanner SF, Leach MO. Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. Radiother Oncol 1997;42:1-15. (Pubitemid 27078106)
4. Yanke BR, Ten Haken RK, Aisen A, Fraass BA, Thornton AF Jr. Design of MRI scan protocols for use in 3-D, CT based treatment planning. Med Dosim 1991;16:205-211.
5. Ten Haken RK, Thornton AF, Sandler HM, et al. A quantitative assessment of the addition of MRI to CT based 3-D treatment planning of brain tumors. Radiother Oncol 1992;25:121-133.
6. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2000;55:317-324.
7. Nestle U, Walter K, Schmidt S, et al. 18F-Deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999;44:593-597.
8. Hannah A, Scott AM, Tochon-Danguy H, et al. Evaluation of 18F-fluorodeoxyglucose positron emission tomography and computed tomography with histolopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002;236:208-217.
9. Goerres GW, Mosna-Firlejczyk K, Steurer J, von Schulthess GK, Bachmann LM. Assessment of clinical utility of 18F-FDG PET in patients with head and neck cancer: a probability analysis. Eur J Nucl Med Mol Imaging 2003;30:562-571. (Pubitemid 36559835)
10. Bruschini P, Giorgetti A, Bruschini L, et al. Positron emission tomography (PET) in the staging of the head neck cancer: comparison between PET and CT. Acta Otorhinolaryngol Ital 2003;23:446-453.
11. Chung NN, Ting LL, Hsu WC, Lui LT, Wang PM. Impact of magnetic resonance imaging versus CT on nasopharyngeal carcinoma: primary tumor target delineation for radiotherapy. Head Neck 2004;26:241-246. (Pubitemid 38292734)
12. Ng SH, Chang TC, Ko SF, et al. Nasopharyngeal carcinoma: MRI and CT assessment. Neuroradiology 1997;39:741-746.
13. Olmi P, Fallai C, Colagrande S, Giannardi G. Staging and follow-up of nasopharyngeal carcinoma: magnetic resonance imaging versus computerized tomography. Int J Radiat Oncol Biol Phys 1995;32:795-800.
14. Leslie A, Fyfe E, Guest P, Goddard P, Kabala JE. Staging of squamous cell carcinoma of the oral cavity and oropharynx: a comparison of MRI and CT in T- and Nstaging. J Comput Assist Tomogr 1999;23:43-49. (Pubitemid 29095466)
15. Emami B, Sethi A, Petruzelli G. Influence of MRI on target volume delineation and IMRT planning in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2003;57:481-488. (Pubitemid 37040945)
16. Krempien RC, Daeuber S, Hensley FW, Wannenmacher M, Harms W. Image fusion of CT and MRI data enables improved target volume definition in 3D-brachytherapy treatment planning. Brachytherapy 2003;2:164-171. (Pubitemid 37205063)
17. Geets X, Daisne JF, Arcangeli S, et al. Inter-observer variability in the delineation of pharyngo-laryngeal tumor, parotid glands and cervical spinal cord: comparison between CT-scan and MRI. Radiother Oncol 2005;77:25-31.
18. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202-3210.
19. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-924. (Pubitemid 32171553)
20. Goerres GW, Schmid DT, Gratz KW, von Schulthess GK, Eyrich GK. Impact of the whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol 2003;39:547-551. (Pubitemid 36694477)
21. Koshy M, Paulino AC, Howell R, et al. F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck 2005;27:494-502.
22. Schmid DT, Stoeckli SJ, Bandhauer F, et al. Impact of positron emission tomography on initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003;113:888-891.
23. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004;231:65-72. (Pubitemid 38375411)
24. Schwartz DL, Ford E, Rajendran J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;61:129-136.
25. Brouwer J, de Bree R, Comans EF, Castelijns JA, Hoekstra OS, Leemans CR. Positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) in the clinically negative neck: is it likely to be superior? Eur Arch Otorhinolaryngol 2004;261:479-483.
26. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma? Head Neck 2002;24:345-349.
27. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255-1260. (Pubitemid 28446051)
28. Stuckensen T, Kovacs AF, Adams S, Baum RP. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 2000;28:319-324. (Pubitemid 32243889)
29. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853-863. (Pubitemid 37194314)
30. Heron DE, Andrade RS, Flickinger J, et al. Hybrid PET-CT simulation for radiation treatment planning in head- and-neck cancers: a brief technical report. Int J Radiat Oncol Biol Phys 2004;60:1419-1424.
31. Scarfone C, Lavely WC, Cmelak AJ, et al. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med 2004;45:543-552.
32. Ashamalla H, Guirgius A, Bieniek E, et al. The impact of positron emission tomography/computed tomography in edge delineation of gross tumor volume for head and neck cancers. Int J Radiat Oncol Biol Phys 2007;68:388-395.
33. Schwartz DL, Ford EC, Rajendran J, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck 2005;27:478-487.
34. Nishioka T, Shiga T, Shirato H, et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 2002;53:1051-1057.
35. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004;233:93-100.
36. Weber AL, al-Arayedh S, Rashid A. Nasopharynx: clinical, pathologic, and radiologic assessment. Neuroimaging Clin N Am 2003;13:465-483.
37. Ford EC, Kinahan PE, Hanlon L, et al. Tumor delineation using PET in head and neck cancers: threshold contouring and lesion volumes. Med Phys 2006;33:4280-4288.
38. Schoder H, Carlson DL, Kraus DH, et al. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006;47:755-762.
39. Zimny M, Wildberger JE, Cremerius U, et al. Combined image interpretation of computed tomography and hybrid PET in head and neck cancer. Nuklearmedizin 2002;41:14-21.